Lexicon Pharmaceuticals | LXRX - Capital De Empréstimo





Capital De Empréstimo Alterar Data
Abbott USD 29.64B 19.74B 2026-03
Acadia Pharmaceuticals USD 0 0 2025-03
Agios Pharmaceuticals USD 1.06M 0 2022-09
Akebia Therapeutics USD 36.39M 11.85M 2026-03
Alnylam Pharmaceuticals USD 2.47B 6.56M 2026-06
AstraZeneca USD 26.01B 46M 2026-06
BioMarin Pharmaceutical USD 1.43B 833.11M 2026-03
Coherus Biosciences USD 51.08M 496K 2025-12
Eli Lilly USD 39.37B 1.5B 2026-03
Halozyme Therapeutics USD 1.94B 206.73M 2026-03
Illumina USD 1.49B 1000K 2026-06
Insmed USD 542.22M 1.25M 2026-03
Ironwood Pharmaceuticals USD 583.99M 14.83M 2024-12
J&J USD 37.34B 183M 2026-06
Lexicon Pharmaceuticals USD 49.68M 276K 2026-03
MacroGenics USD 68.71M 1.29M 2026-03
MannKind USD 548.07M 371K 2026-03
Merck USD 46.67B 77M 2026-03
Moderna USD 597M 6M 2026-06
Novartis USD 37.49B 42M 2026-06
PTC Therapeutics USD 535.52M 248.58M 2026-06
Puma Biotechnology USD 10.87M 222K 2025-06
Sarepta Therapeutics USD 838.16M 9.19M 2026-03
Thermo Fisher Scientific USD 39.18B 890M 2026-06
Ultragenyx Pharmaceutical USD 1.13B 19M 2026-03
United Therapeutics USD 100M 100M 2024-06
Vanda Pharmaceuticals USD 3.15M 3.15M 2024-12